{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:34:14Z","timestamp":1791995654500,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cgh.2024.07.033","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T10:29:06Z","timestamp":1725618546000},"page":"250-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-3956","authenticated-orcid":false,"given":"Mohammad","family":"Shehab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Alrashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulwahab","family":"Alsayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Aldallal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.07.033_bib1","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.07.033_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.07.033_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.crohns.2011.06.009","article-title":"Scientific Committee of the European Crohn's and Colitis Organization. Results from the 2nd Scientific Workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease","volume":"5","author":"Peyrin-Biroulet","year":"2011","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.033_bib4","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","article-title":"Mucosal healing in inflammatory bowel diseases: a systematic review","volume":"61","author":"Neurath","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.07.033_bib5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.07.033_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/gut.32.2.174","article-title":"Microscopic activity in ulcerative colitis: what does it mean?","volume":"32","author":"Riley","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.07.033_bib7","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/ecco-jcc\/jjw112","article-title":"Histological outcomes and predictive value of faecal markers in moderately to severely active ulcerative colitis patients receiving infliximab","volume":"10","author":"Magro","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.033_bib8","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","article-title":"Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)","volume":"161","author":"Peyrin-Biroulet","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.07.033_bib9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.cgh.2017.02.016","article-title":"Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes","volume":"15","author":"Christensen","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.07.033_bib10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1053\/j.gastro.2007.08.001","article-title":"Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study","volume":"133","author":"Gupta","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.07.033_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/2050640617752207","article-title":"Prognostic value of histological activity in patients with ulcerative colitis in deep remission: a prospective multicenter study","volume":"6","author":"Lobat\u00f3n","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2024.07.033_bib13","doi-asserted-by":"crossref","first-page":"i404","DOI":"10.1093\/ecco-jcc\/jjac190.0383","article-title":"P253 Histological remission and activity as predictor of relapse, hospitalization, and surgery in ulcerative colitis: systematic review and meta-analysis","volume":"17","author":"Shehab","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.033_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.033_bib15","article-title":"The efficacy of currently licensed biologics for treatment of ulcerative colitis: a literature review","volume":"15","author":"Awan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.cgh.2024.07.033_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2024.07.033_bib17","article-title":"RoB 2: a revised tool for\u00a0assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2024.07.033_bib18","author":"Higgins"},{"key":"10.1016\/j.cgh.2024.07.033_bib19","author":"Higgins"},{"key":"10.1016\/j.cgh.2024.07.033_bib20","series-title":"NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials","author":"Dias","year":"2011"},{"key":"10.1016\/j.cgh.2024.07.033_bib21","series-title":"NICE DSU Technical Support Document 7: Evidence synthesis of treatment efficacy in decision making: a reviewer\u2019s checklist","author":"Ades","year":"2012"},{"key":"10.1016\/j.cgh.2024.07.033_bib22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.07.033_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.07.033_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","article-title":"Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.07.033_bib25","doi-asserted-by":"crossref","first-page":"S073","DOI":"10.1093\/ecco-jcc\/jjy222.105","article-title":"DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis","volume":"13","author":"Li","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.033_bib26","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.07.033_bib27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.07.033_bib28","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.07.033_bib29","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"True North Study Group. Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.07.033_bib30","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.07.033_bib31","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.07.033_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/apt.15568","article-title":"Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission","volume":"51","author":"Cushing","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.07.033_bib33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/gutjnl-2015-309598","article-title":"Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up","volume":"65","author":"Bryant","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.07.033_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/apt.13653","article-title":"Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis","volume":"44","author":"Sandborn","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.07.033_bib35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.14309\/ajg.0000000000000111","article-title":"Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials","volume":"114","author":"Battat","year":"2019","journal-title":"Am J Gastroenterology"},{"key":"10.1016\/j.cgh.2024.07.033_bib36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.dld.2013.06.010","article-title":"Definition and evaluation of mucosal healing in clinical practice","volume":"45","author":"Mazzuoli","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2024.07.033_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/17474124.2014.902302","article-title":"Mucosal healing as a treatment for IBD?","volume":"8","author":"Papi","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.07.033_bib39","first-page":"915","article-title":"Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease","volume":"10","author":"Pineton de Chambrun","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.07.033_bib40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"European Crohn\u2019s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.033_bib41","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/j.gastro.2020.08.037","article-title":"Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis","volume":"159","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.07.033_bib42","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/ecco-jcc\/jjac001","article-title":"Combined histo-endoscopic remission but not endoscopic healing alone in ulcerative colitis is associated with a mucosal transcriptional profile resembling healthy mucosa","volume":"16","author":"Hern\u00e1ndez-Rocha","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.07.033_bib43","first-page":"3378","article-title":"Therapeutic drug monitoring of infliximab in acute severe ulcerative colitis","volume":"12","author":"Gordon","year":"2023","journal-title":"J\u00a0Clin Med"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524007675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524007675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:16:14Z","timestamp":1737616574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524007675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1542356524007675"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.07.033","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute","name":"copyright","label":"Copyright"}]}}